OncoMatch/Clinical Trials/NCT05009082
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Is NCT05009082 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Carboplatin and Paclitaxel for ovarian cancer.
Treatment: Carboplatin · Paclitaxel · Bevacizumab · Niraparib — This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advanced ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO III, FIGO IV, FIGO IIIB, FIGO IIIC (FIGO)
Excluded: Stage FIGO IIIA2 WITHOUT NODAL INVOLVEMENT
Grade: high grade
FIGO III/IV (except FIGO stage IIIA2 without nodal involvement) according to recent FIGO classification (= FIGO stage IIIB - IV according to FIGO 2009 classification)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic treatment for ovarian cancer
Cannot have received: parp inhibitor
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 9 g/dL (can be post-transfusion)
Kidney function
Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 30 mL/min. Urine dipstick for proteinuria < 2+. If urine dipstick is ≥ 2+, 24 hour urine must demonstrate ≤ 1 g of protein in 24 hours.
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) OR direct bilirubin ≤ 1.0 x ULN. ASAT/SGOT and ALAT/SGPT ≤ 2.5 x ULN, unless liver metastases are present, in case of liver metastases values must be ≤ 5 x ULN.
Cardiac function
Patients must have normal blood pressure (BP) or adequately treated and controlled BP, with a systolic BP of ≤ 140 mmHg and diastolic BP of ≤ 90 mmHg for eligibility.
Adequate bone marrow function...Adequate coagulation parameters...Adequate liver and kidney function...Patients must have normal blood pressure (BP) or adequately treated and controlled BP
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify